Qaal
2021-05-04
Easy hold and moon.
After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>在昨天飙升近 24% 后，OCGN 在盘前交易中下跌 4%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":106287639,"tweetId":"106287639","gmtCreate":1620124650321,"gmtModify":1634207645089,"author":{"id":3577432645863048,"idStr":"3577432645863048","authorId":3577432645863048,"authorIdStr":"3577432645863048","name":"Qaal","avatar":"https://static.tigerbbs.com/0ebae6fa58e32daca8a545858cb2b589","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Easy hold and moon. </p></body></html>","htmlText":"<html><head></head><body><p>Easy hold and moon. </p></body></html>","text":"Easy hold and moon.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/106287639","repostId":1157490418,"repostType":4,"repost":{"id":"1157490418","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620120727,"share":"https://www.laohunote.com/m/news/1157490418?lang=zh_CN&edition=full","pubTime":"2021-05-04 17:32","market":"us","language":"en","title":"After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>在昨天飙升近 24% 后，OCGN 在盘前交易中下跌 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157490418","media":"Tiger Newspress","summary":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares ","content":"<p><p style=\"text-align:left;\">(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.</p><p><blockquote><p style=\"text-align:left;\">（5月4日）在昨天飙升近24%后，OCGN在盘前交易中下跌4%。</p></blockquote></p><p><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p>Shares of <b>Ocugen</b>(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.</p><p><blockquote>股份<b>奥库根</b>（纳斯达克股票代码：OCGN）周一飙升 23.8%，此前这家生物技术公司发布了对科瓦克辛（该公司希望将 COVID-19 候选疫苗）的研究数据，该公司希望将其引入美国市场。</blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.</p><p><blockquote>印度医学研究委员会（ICMR）-国家病毒学研究所的研究人员认为，科瓦克辛可以抵御多种冠状病毒株。科瓦克辛似乎对一种来自巴西的变种B.1.128.2有效。之前的一项研究表明，科瓦克辛还可以抵御来自英国和印度的变种。</blockquote></p><p>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"</p><p><blockquote>Ocugen 联合创始人兼首席执行官 Shankar Musunuri 博士在一份新闻稿中表示：“科瓦克辛在迄今为止进行的所有研究中继续显示出强劲的结果。”“我们仍然相信这种疫苗是我们国家抗击这一流行病的重要工具。”</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.</p><p><blockquote>Musunuri 表示，Ocugen 向美国提交了一份全面的药物主文件。美国食品药品监督管理局（FDA）。该公司还在准备申请紧急使用授权。Ocugen 与其药物开发合作伙伴、总部位于印度的 Bharat Biotech 达成的协议，如果获得监管部门授权，它将获得在美国销售科瓦克辛的任何利润的 45% 份额。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>在昨天飙升近 24% 后，OCGN 在盘前交易中下跌 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter surging nearly 24% yesterday, OCGN dipped 4% in premarket trading<blockquote>在昨天飙升近 24% 后，OCGN 在盘前交易中下跌 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-05-04 17:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p style=\"text-align:left;\">(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.</p><p><blockquote><p style=\"text-align:left;\">（5月4日）在昨天飙升近24%后，OCGN在盘前交易中下跌4%。</p></blockquote></p><p><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p>Shares of <b>Ocugen</b>(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.</p><p><blockquote>股份<b>奥库根</b>（纳斯达克股票代码：OCGN）周一飙升 23.8%，此前这家生物技术公司发布了对科瓦克辛（该公司希望将 COVID-19 候选疫苗）的研究数据，该公司希望将其引入美国市场。</blockquote></p><p><b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.</p><p><blockquote>印度医学研究委员会（ICMR）-国家病毒学研究所的研究人员认为，科瓦克辛可以抵御多种冠状病毒株。科瓦克辛似乎对一种来自巴西的变种B.1.128.2有效。之前的一项研究表明，科瓦克辛还可以抵御来自英国和印度的变种。</blockquote></p><p>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"</p><p><blockquote>Ocugen 联合创始人兼首席执行官 Shankar Musunuri 博士在一份新闻稿中表示：“科瓦克辛在迄今为止进行的所有研究中继续显示出强劲的结果。”“我们仍然相信这种疫苗是我们国家抗击这一流行病的重要工具。”</blockquote></p><p><b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.</p><p><blockquote>Musunuri 表示，Ocugen 向美国提交了一份全面的药物主文件。美国食品药品监督管理局（FDA）。该公司还在准备申请紧急使用授权。Ocugen 与其药物开发合作伙伴、总部位于印度的 Bharat Biotech 达成的协议，如果获得监管部门授权，它将获得在美国销售科瓦克辛的任何利润的 45% 份额。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157490418","content_text":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares of Ocugen(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.So whatResearchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"Now whatMusunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":3979,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/106287639"}
精彩评论